On February 22, 2021 Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, reported the company will participate at the Cowen 41st Annual Virtual Health Care Conference, H.C. Wainwright Global Life Sciences Conference, and Oppenheimer 31st Annual Virtual Healthcare Conference (Press release, Alpine Immune Sciences, FEB 22, 2021, View Source [SID1234575363]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cowen 41st Annual Virtual Health Care Conference
Date: Monday, March 1, 2021
Time: 10:20 a.m. ET/7:20 a.m. PT
Event: Novel IO Panel

H.C. Wainwright Global Life Sciences Conference
Date: Tuesday, March 9, 2021
Time: Available on demand beginning 7:00 a.m. ET/4:00 a.m. PT
Event: Company Presentation

Oppenheimer 31st Annual Virtual Healthcare Conference
Date: Wednesday, March 17, 2021
Time: 1:50 p.m. ET/10:50 a.m. PT
Event: Company Presentation

A webcast of the H.C. Wainwright and Oppenheimer presentations will be available online in the investor relations section of the company’s website at View Source A replay of the presentations will be available on the company website for 90 days following the webcast.

On February 22, 2021 NantHealth, Inc. (NASDAQ-GS: NH), a provider of enterprise solutions that help businesses transform complex data into actionable insights, reported that it will report financial results for its 2020 fourth quarter and full year on Thursday, February 25, 2021, after market close (Press release, NantHealth, FEB 22, 2021, View Source [SID1234575379]). NantHealth management will host a conference call that same day at 1:30 p.m. PT (4:30 p.m. ET) to review the company’s performance.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call will be available to interested parties by dialing 844-309-3709 from the U.S. or Canada, or 281-962-4864 from international locations, passcode 9786375. The call will be broadcast via the Internet at www.nanthealth.com.

On February 22, 2021 Agilent Technologies Inc. (NYSE: A) reported that the U.S. Food and Drug Administration (FDA) has approved the company’s PD-L1 IHC 22C3 pharmDx assay for expanded use in patients with non-small cell lung cancer (NSCLC) (Press release, Agilent, FEB 22, 2021, View Source [SID1234575395]). PD-L1 IHC 22C3 pharmDx can now be used as an aid in identifying NSCLC patients with tumor PD-L1 expression of Tumor Proportion Score (TPS) ≥ 50% for treatment with Libtayo (cemiplimab-rwlc). This announcement underscores Agilent’s continuing commitment to the development of IHC-based diagnostics for cancer therapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"With the FDA approval of PD-L1 IHC 22C3 pharmDx as a companion diagnostic for treatment with Libtayo monotherapy in advanced NSCLC, Agilent further strengthens its ability to elevate pathologist confidence in reporting results to oncologists and bolsters our role as a global pioneer in developing companion diagnostics for targeted treatments."

Lung cancer is the leading cause of cancer death in both men and women in the United States, with NSCLC making up 85% of all lung cancer cases.1,2 PD-L1 expression is a biomarker for response to anti-PD-1 therapy in NSCLC; this expanded indication enables pathologists to identify patients with advanced NSCLC who may be eligible for treatment with Libtayo. Currently, PD-L1 IHC 22C3 pharmDx is the only companion diagnostic with FDA approval for this use.

"Anti-PD-1 therapies, including Libtayo, continue to broaden the potential for the treatment of patients across different cancer types," said Sam Raha, president of Agilent’s Diagnostics and Genomics Group. "With the FDA approval of PD-L1 IHC 22C3 pharmDx as a companion diagnostic for treatment with Libtayo monotherapy in advanced NSCLC, Agilent further strengthens its ability to elevate pathologist confidence in reporting results to oncologists and bolsters our role as a global pioneer in developing companion diagnostics for targeted treatments."

Regeneron and Sanofi developed Libtayo and partnered with Agilent for the use of PD-L1 IHC 22C3 pharmDx to evaluate PD-L1 expression in patients in the pivotal EMPOWER-Lung 1 clinical trial.3

PD-1 immunotherapies such as Libtayo offer new treatment options for patients with advanced NSCLC, for whom the 60-month overall survival rate is 0–10% in patients with stage IVA–IVB disease.2

Libtayo is a fully-human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T-cells. By binding to PD-1, Libtayo has been shown to block cancer cells from using the PD-1 pathway to suppress T-cell activation.3

On February 22, 2021 Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, reported that it will report its full year 2020 financial results on Thursday, February 25th, 2021 (Press release, Altimmune, FEB 22, 2021, View Source [SID1234575746]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Altimmune management will host a conference call for investors beginning at 8:30 am ET on Thursday, February 25th, 2021 to discuss financial results and provide a business update.

On February 22, 2021 Wugen Inc., a biotechnology company developing novel, universal allogeneic cellular therapies, reported that it has entered into an exclusive license agreement with Washington University in St. Louis, one of the world’s leading research institutions, for the development of Wugen’s Memory Natural Killer (NK) Cell program (Press release, Wugen, FEB 22, 2021, View Source [SID1234576287]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

While currently approved autologous cellular therapies have been shown to effectively treat B cell cancers, there remains significant unmet need for treating other cancers, including solid tumors. Memory NK cells have been demonstrated in the clinic to be safe and effective, with several significant advantages over existing therapies. By dovetailing its extensive experience in developing "off-the-shelf" CAR-T with Memory NK cells, Wugen will be able to rapidly deliver its off-the-shelf Memory NK platform to patients.

Todd Fehniger, M.D., Ph.D., Professor of Medicine, Oncology Division, at Washington University and a cellular therapy and transplantation specialist, will be leading these efforts. "Wugen’s Memory Natural Killer (NK) Cell-based therapy program will open up new avenues to explore treatment options for incurable and intractable diseases such as Acute Myeloid Leukemia and Multiple Myeloma, for which current treatment options have limited or no benefit," said Dr. Fehniger. "I look forward to partnering with Wugen to advance these NK cell programs and deliver these much-needed solutions to patients worldwide, and to also expand the impact of memory NK cells to solid tumor immunotherapy."

"This agreement expands our ongoing collaboration with one of the leading research institutions to develop cutting edge cell therapies to treat solid and hematological cancers," said John McKearn, Ph.D., CEO of Wugen. "Our innovative approach is aimed to treat patients who currently lack therapeutic options."